Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Ellen Beasley's Biography



Ellen Beasley, Senior Vice President, Genomic Health Inc

Ellen Beasley has over 20 years of product development and program management experience in biotechnology and genomics sciences. She brings a record of successful integration and application of bioinformatics, genetics and genomics platforms to advance and accelerate life sciences instrument, diagnostics and therapeutics product discovery and development. Ellen started her career in human genomics at the Stanford Human Genome Center and lead the team developing physical maps of the human genome. She then moved to Celera Genomics and participated in the genome sequencing and gene discovery efforts for the human genome. After the completion of the human genome, Ellen managed various discovery efforts to apply the human genome, including drug target discovery efforts, investigation of the genetic basis of autoimmune disease and companion diagnostic partnership development. Ellen then moved to Perlegen Sciences where she was SVP of R&D Operations, managing companion diagnostic programs and building the CLIA lab for commercialization of a breast cancer risk assay. In 2009, Ellen joined Life Technologies and was VP of Biological Information Systems, leading a team to develop methods and software tools to exploit the data from next generation sequencers. Since joining Genomic Health in 2013, Ellen has focused on the application of next generation technologies, including sequencing and liquid-based biopsy, to discover and develop Genomic Health’s next generation of products to serve patients living with cancer. Ellen received a B.S. in Biology from Trinity College (Hartford, CT) and a Ph.D. in Molecular Genetics & Cell Biology from The University of Chicago, she completed post-doctoral training at the Biozentrum of the University of Basel in Switzerland and Stanford University. Ellen is an inventor on approximately 170 patents.

Ellen Beasley Image

Delivering on the Promise: Progress and Pitfalls Demonstrating the Value of Liquid Biopsies in Improving Cancer Care

Thursday, 5 October 2017 at 09:00

Add to Calendar ▼2017-10-05 09:00:002017-10-05 10:00:00Europe/LondonDelivering on the Promise: Progress and Pitfalls Demonstrating the Value of Liquid Biopsies in Improving Cancer CareLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Liquid biopsy products and applications have proliferated over the past several years, suggesting early enthusiasm for these non-invasive diagnostic tests was justified.  A broad variety of technologies are now being applied to critical decision points across the patient journey.  Early applications have focused on late stage cancer, when treatment selection is complex and tissue biopsy may be neither feasible nor representative.  More recently, several treatment monitoring assays have also been released and the promise of liquid biopsy for cancer screening may be tantalizingly close.  The impressive progress in the field of liquid biopsy is tempered by evolving standards of evidence to support physician adoption, guideline inclusion and reimbursement.  I will review some of the emerging trends in the field, new product applications and the technical and commercial challenges that players will need to continue to manage.


Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com